We found that UDCA treatment suppressed the mean serum level values of CD163 for all PBC patient groups (916 ng/mL before UDCA vs. 717 ng/mL after UDCA), and the differences were more pronounced when the values of CD163 concentrations were compared individually for each patient before UDCA vs. after UDCA (paired t-test p = 0.04; Figure 3B). This evidence concerns the gene CD163 and primary biliary cholangitis.